BridgeBio Pharma Inc
For the period ended Mar 31, 2025. Filed Apr 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed Apr 29, 2025
BBIO$78.67+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(169,608) | $(36,160) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 25,882 | 17,057 |
| Loss on extinguishment of debt | 21,155 | 26,590 |
| Accretion of debt | 25,641 | 2,015 |
| Depreciation and amortization | 1,284 | 1,596 |
| Noncash lease expense | 994 | 1,069 |
| Net loss from equity method investments | 15,556 | — |
| Gain from investment in equity securities, net | — | (8,136) |
| Other noncash adjustments, net | (3,973) | 1,631 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (110,543) | (233,743) |
| Inventories | (3,193) | — |
| Prepaid expenses and other current assets | (487) | (3,345) |
| Other assets | 1,587 | 444 |
| Accounts payable | 17,571 | (5,927) |
| Accrued compensation and benefits | (19,363) | (14,969) |
| Accrued research and development liabilities | (642) | 11,168 |
| Operating lease liabilities | (1,470) | (1,595) |
| Deferred revenue | (2,571) | 24,024 |
| Other current liabilities | 2,945 | (1,256) |
| Net cash used in operating activities | (199,235) | (219,537) |
| Investing activities: | ||
| Purchases of marketable securities | — | (44,395) |
| Purchases of investments in equity securities | — | (20,271) |
| Proceeds from sales of investments in equity securities | — | 63,229 |
| Proceeds from special cash dividends received from investments in equity securities | — | 25,682 |
| Payment for an intangible asset | (1,595) | (797) |
| Purchases of property and equipment | — | (695) |
| Net cash provided by (used in) investing activities | (1,595) | 22,753 |
| Financing activities: | ||
| Proceeds from issuance of 2031 Notes | 575,000 | — |
| Issuance costs and discounts associated with 2031 Notes | (12,034) | — |
| Repurchase of common stock | (48,276) | — |
| Proceeds from term loan under Amended Financing Agreement | — | 450,000 |
| Issuance costs and discounts associated with term loan under Amended Financing Agreement | — | (12,254) |
| Repayment of term loans | (459,000) | (473,417) |
| Repayment of deferred royalty obligation | (144) | — |
| Proceeds from issuance of common stock through public offerings, net | — | 315,254 |
| Proceeds from BridgeBio common stock issuances under ESPP | 3,237 | 2,364 |
| Proceeds from stock option exercises, net of repurchases | 2,521 | 537 |
| Transactions with noncontrolling interests | 800 | — |
| Repurchase of RSU shares to satisfy tax withholding | (1,776) | (2,936) |
| Net cash provided by financing activities | 60,328 | 279,548 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (140,502) | 82,764 |
| Cash, cash equivalents and restricted cash at beginning of period | 683,244 | 394,732 |
| Cash, cash equivalents and restricted cash at end of period | $542,742 | $477,496 |
Condensed Consolidated Statements of Cash Flows
(Continued)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Supplemental Disclosure of Cash Flow Information: | ||
| Cash paid for interest | $23,271 | $35,315 |
| Supplemental Disclosures of Noncash Investing and Financing Information: | ||
| Recognized intangible asset recorded to "Other current liabilities" | $4,500 | $— |
| Unpaid issuance costs associated with term loan under Amended Financing Agreement | $— | $3,732 |
| Unpaid public offering issuance costs | $— | $513 |
| Deferred and unpaid issuance costs recorded to “Other current liabilities” | $— | $458 |
| Unpaid property and equipment | $337 | $70 |
| Transfers to noncontrolling interests | $(824) | $(1,857) |
| Reconciliation of Cash, Cash Equivalents and Restricted Cash: | ||
| Cash and cash equivalents | $540,599 | $475,222 |
| Restricted cash — Included in “Prepaid expenses and other current assets” | 126 | 131 |
| Restricted cash — Included in “Other assets” | 2,017 | 2,143 |
| Total cash, cash equivalents and restricted cash at end of periods shown in the condensed consolidated statements of cash flows | $542,742 | $477,496 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.